Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Nov 14, 2022 (4 years ago)

Phenytoin Sodium Injection

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Labeling: Not elsewhere classified; the product is being recalled because of customer complaints that the primary vial label was missing a barcode.

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

Phenytoin Sodium Injection, USP 100 mg/2 mL, NDC 42192-614-02, packaged in 10 x 2 mL vials per carton, NDC 42192-614-10, Rx only, Manufactured for: Acella Pharmaceuticals, LLC Alpharetta, GA 30005

Affected NDCs 42192-0614-02 42192-0614-10

Compare with the code on your package — it is the most precise check available.

Drug: Phenytoin

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Phenytoin Sodium
NDC 42192-0614
50 mg/mL Injection
Intramuscular|intravenous
Acella Pharmaceuticals, LLC Rx
Recalling firm
Acella Pharmaceuticals, LLC
NDC code
42192-614-02
Origin
GA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0069-2023 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Phenytoin recalls

See all
Class I · High risk

Phenytoin Oral Suspension

Failed Content Uniformity Specifications

Terminated Wrong potency / content The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories NDC 0904-7079-24 D-0153-2024
Class II · Moderate risk

Extended Phenytoin Sodium Capsules

Failed Dissolution Specifications: Out-of-specification results for dissolution (above specification)

Terminated Dissolution failure Amneal Pharmaceuticals of New York, LLC NDC 65162-212-10 D-0876-2023
Class III · Low risk

Phenytoin Sodium Injection

Labeling: Not elsewhere classified; the product is being recalled because of customer complaints that the primary vial label was missing a barcode.

Terminated Labeling / mix-up Acella Pharmaceuticals, LLC NDC 42192-614-05 D-0070-2023
Class I · High risk

Phenytoin Oral Suspension USP

Resuspension Problems: Two lots of Phenytoin Oral Suspension USP 125mg/5mL may coagulate and may not resuspend as per the label copy instructions.

Terminated Failed specification Taro Pharmaceuticals U.S.A., Inc. NDC 51672-4069-1 D-0863-2020

Other recalls by Acella Pharmaceuticals, LLC

All 2022 recalls
Class II · Moderate risk

Naproxen Oral Suspension

Chemical contamination; presence of lead and lithium above specification

Ongoing Chemical / undeclared Acella Pharmaceuticals, LLC NDC 42192-619-16 D-0523-2026
Class II · Moderate risk

Doxycycline Hyclate Tablets

Failed dissolution specifications: Stability testing found that the lot did not meet dissolution specifications.

Ongoing Dissolution failure Acella Pharmaceuticals, LLC NDC 42192-501-05 D-0014-2026